Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 19, 2026

Tikehau Capital Strategic update

View original at finance.yahoo.com
Tikehau Capital Strategic update A new chapter of growth focused on profitability and long-term value creation PARIS, February 19, 2026--(BUSINESS WIRE)--Regulatory News: Tikehau Capital (Paris:TKO): As part of today’s 2025 full-year results, Tikehau Capital’s co-founders and executive team will present an update of th…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Core FRE margin to reach between 45-50% by 2029, versus 41% in 2025

    80% confidence
  • An estimated $130 trillion capex surge between 2022 and 2027 driven by resilience and transformation

    80% confidence
  • 2026 milestone targets: between €175m and €225m of FRE (37-76% growth vs. 2025, and approximately 20-50% above market expectations)

    80% confidence
  • Global private markets AuM expected to grow from approximately $26 trillion in 2022 to about $61 trillion by 2032

    80% confidence
  • Cumulative net inflows to exceed €34bn over 2026-2029, representing a 22% increase vs. €28bn raised between 2022-2025

    80% confidence
  • Europe offers compelling entry points amid rising dispersion, supported by policy tailwinds, more attractive valuations, and lower average leverage than the US

    80% confidence
  • Tikehau Capital aims to accelerate profitability generation for its Asset Management platform, building on its strong foundations

    80% confidence
  • 2026 milestone targets: between 13% and 16% of return on equity, compared to market expectations of 8%

    80% confidence
  • 2026 milestone targets: between €420m and €520m of Net result, Group share, compared to €136m in 2025, approximately 50-80% above market expectations

    80% confidence
  • PRE is expected to become a more material driver of profitability going forward as assets mature

    80% confidence
  • Deployment has been consistently selective with >95% exclusion rate since IPO

    80% confidence
  • The Group's balance sheet will be allocated with greater strategic selectivity, supporting improved portfolio velocity and returns generation

    80% confidence
  • Value-add strategies reached approximately 25% of AuM as of end-2025, compared to less than 1% at IPO

    80% confidence
  • International investors now represent 46% of AuM, compared to 20% at end-2016

    80% confidence
  • Since the end of October 2025, there has been a continued change in the environment characterized by uncertainties from macroeconomic and geopolitical standpoints

    80% confidence
  • The Group has expanded with 12 new strategies launched since IPO

    80% confidence
  • 2026 milestone targets: at least €60bn of AuM (14% growth vs. 2025 and 3% above market expectations)

    80% confidence
  • Tikehau Capital remains committed to maintaining its Investment Grade rating and distributing over 80% of its Asset Management EBIT to shareholders

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com